JAMP-CIPROFLOXACIN 250 MG
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 250 MG · DIN 02380358 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-CIPROFLOXACIN?
JAMP-CIPROFLOXACIN 250 MG contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02380358, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Mar-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-CIPROFLOXACIN used for?
Respiratory, urinary tract, skin/soft tissue, bone/joint infections; infectious diarrhea; typhoid fever; uncomplicated gonorrhea; meningococcal carriers; chronic bacterial prostatitis; acute sinusitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02380358 |
|---|---|
| Brand name | JAMP-CIPROFLOXACIN |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 250 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA02 CIPROFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Mar-2012 |
| Original market date | 2012-03-13 00:00:00 |
How is it administered?
Adults: 250-750 mg every 12 hours depending on infection. Gonorrhea: 500 mg once. Meningococcal carrier: 750 mg once. Take 2h before or 6h after antacids/minerals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in provided text.
How is it supplied?
250 mg: Bottles of 100; 500 mg: Bottles of 100 and 500; 750 mg: Bottles of 50.
Contraindications
Hypersensitivity to ciprofloxacin or other quinolones; concurrent administration with agomelatine or tizanidine.
Warnings and precautions
Disabling/persistent reactions (tendonitis, neuropathy, neuropsychiatric); QT prolongation; serious hypersensitivity; aortic aneurysm risk; blood glucose disturbances; hepatic failure.
Is CIPROFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA02 CIPROFLOXACIN. 29 of 139 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT CIPROFLOXACIN | 250 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247339 |
| ACT CIPROFLOXACIN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247340 |
| ACT CIPROFLOXACIN | 750 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247341 |
| AURO-CIPROFLOXACIN | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381907 |
| AURO-CIPROFLOXACIN | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381923 |
| BIO-CIPROFLOXACIN | 500 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444887 |
| CIPRO ORAL SUSPENSION | 500 MG / 5 ML | SUSPENSION | BAYER INC | MARKETED | DIN 02237514 |
| CIPROFLOXACIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353318 |
| CIPROFLOXACIN | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02386119 |
| CIPROFLOXACIN | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353326 |
Who else supplies CIPROFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIPROFLOXACIN appears in 449 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.